[Source]
ST. PAUL, MN – April 23, 2012 – 3M Drug Delivery Systems announces the expansion of the pressurized metered dose inhaler (pMDI) fill line at its facility in Northridge, Calif., significantly extending the company’s manufacturing capability. The addition of the pressure fill line complements the existing state-of-the-art cold fill line in the facility and enhances 3M Drug Delivery Systems’ inhalation manufacturing services for customers. With the expansion, 3M Northridge can manufacture new and marketed pressure filled pMDI products for its customers on a global scale, solidifying 3M Drug Delivery Systems’ “start-to-finish” reputation as a single-source provider for the development and commercialization of the pMDI. Additionally, the company has established a Qualified Person (QP) release route to Europe.
“This expansion reflects our continued growth,” said Louise Righton, global divisional marketing manager for 3M Drug Delivery Systems. “Customers are responding enthusiastically to our manufacturing expertise, which capitalizes on Lean Six Sigma methodology to drive efficiency.”
Since creating the first metered dose inhaler 50 years ago, 3M Drug Delivery Systems has continued to lead in the development of new technologies and manufacturing services for inhaled drug delivery. 3M Drug Delivery Systems currently has four strategically located pMDI filling sites and the company has experience manufacturing products for distribution in more than 60 countries worldwide.
In the early stages of product development, 3M Drug Delivery Systems offers formulation screening and optimization for both solutions and suspensions, including particle engineering to improve dosing performance. The company also offers an array of pMDI components such as valves and canisters that can be customized to fit customers’ needs, as well as actuators and dose counters, which improve the patient experience.
Learn more about 3M’s metered dose inhalers and manufacturing expertise at 3m.com/dds or visit 3M Drug Delivery Systems at the INTERPHEX 2012 conference at booth #3155, May 1-3 in New York, N.Y., or at the 2012 Respiratory Drug Delivery (RDD) conference at booth #70, May 13-17 in Phoenix, Ariz.
About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology. For more information, please visit www.3M.com/dds or call 1-800-643-8086.
About 3M
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $30 billion in sales, 3M employs about 84,000 people worldwide and has operations in more than 65 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.
3M is a trademark of 3M Company.
Contact:
Michael Gugala
Karwoski & Courage
(612) 342-9604
[email protected]
Mary Kokkinen
3M Public Relations and Corporate Communications
(651) 733-8806
[email protected]
3M Drug Delivery Systems
3M Center, Bldg 275-3E-10
St. Paul, MN 55144